These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35131133)

  • 21. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents.
    June Choe Y; Yi S; Hwang I; Kim J; Park YJ; Cho E; Jo M; Lee H; Hwa Choi E
    Vaccine; 2022 Jan; 40(5):691-694. PubMed ID: 35012777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
    Bravo L; Smolenov I; Han HH; Li P; Hosain R; Rockhold F; Clemens SAC; Roa C; Borja-Tabora C; Quinsaat A; Lopez P; López-Medina E; Brochado L; Hernández EA; Reynales H; Medina T; Velasquez H; Toloza LB; Rodriguez EJ; de Salazar DIM; Rodríguez CA; Sprinz E; Cerbino-Neto J; Luz KG; Schwarzbold AV; Paiva MS; Carlos J; Montellano MEB; de Los Reyes MRA; Yu CY; Alberto ER; Panaligan MM; Salvani-Bautista M; Buntinx E; Hites M; Martinot JB; Bhorat QE; Badat A; Baccarini C; Hu B; Jurgens J; Engelbrecht J; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R
    Lancet; 2022 Jan; 399(10323):461-472. PubMed ID: 35065705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data.
    Chodick G; Tene L; Rotem RS; Patalon T; Gazit S; Ben-Tov A; Weil C; Goldshtein I; Twig G; Cohen D; Muhsen K
    Clin Infect Dis; 2022 Feb; 74(3):472-478. PubMed ID: 33999127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Borobia AM; Carcas AJ; Pérez-Olmeda M; Castaño L; Bertran MJ; García-Pérez J; Campins M; Portolés A; González-Pérez M; García Morales MT; Arana-Arri E; Aldea M; Díez-Fuertes F; Fuentes I; Ascaso A; Lora D; Imaz-Ayo N; Barón-Mira LE; Agustí A; Pérez-Ingidua C; Gómez de la Cámara A; Arribas JR; Ochando J; Alcamí J; Belda-Iniesta C; Frías J;
    Lancet; 2021 Jul; 398(10295):121-130. PubMed ID: 34181880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.
    Chapin-Bardales J; Myers T; Gee J; Shay DK; Marquez P; Baggs J; Zhang B; Licata C; Shimabukuro TT
    Vaccine; 2021 Nov; 39(48):7066-7073. PubMed ID: 34763946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study.
    Kian W; Zemel M; Kestenbaum EH; Rouvinov K; Alguayn W; Levitas D; Ievko A; Michlin R; Abod MA; Massalha I; Chernomordikov E; Sharb AA; Shalata W; Levison E; Roisman LC; Lavrenkov K; Peled N; Nesher L; Yakobson A
    Medicine (Baltimore); 2022 Jan; 101(2):e28561. PubMed ID: 35029223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
    John BV; Deng Y; Scheinberg A; Mahmud N; Taddei TH; Kaplan D; Labrada M; Baracco G; Dahman B
    JAMA Intern Med; 2021 Oct; 181(10):1306-1314. PubMed ID: 34254978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer.
    Goshen-Lago T; Waldhorn I; Holland R; Szwarcwort-Cohen M; Reiner-Benaim A; Shachor-Meyouhas Y; Hussein K; Fahoum L; Baruch M; Peer A; Reiter Y; Almog R; Halberthal M; Ben-Aharon I
    JAMA Oncol; 2021 Oct; 7(10):1507-1513. PubMed ID: 34236381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
    Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
    Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
    Chu L; McPhee R; Huang W; Bennett H; Pajon R; Nestorova B; Leav B;
    Vaccine; 2021 May; 39(20):2791-2799. PubMed ID: 33707061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.